Since May 2015, the Zika virus epidemic has plagued many nations and continues to spread to more. However, the mosquito-transmitted disease may soon be eradicated with the development of a new Zika vaccine.
On Monday, June 20, 2016, reports went viral when the U.S. Centers for Disease Control and Prevention (CDC) approved the following drug developers to initiate human clinical trials for the Zika Vaccine: Inovio Pharmaceuticals Inc, based in Plymouth Meeting, Pennsylvania, and GeneOne Life Sciences Inc, based in Seoul, South Korea.
Both Inovio and GeneOne have co-created vaccines for Ebola and MERS, which are also undergoing efficacy testing.
The vaccine, labeled GLS-5700, will be enrolled in a phase I study. This study will include 40 healthy volunteer human test subjects who will be given the vaccine to measure the safety, tolerability and effectiveness of the drug.
The initial trials are scheduled to begin July 2016, and should they yield successful results, they will be promoted to phase II clinical trials. These trials will test GLS-5700’s efficacy on people who have already contracted the Zika virus.
If these phase II trials are successful, then the Zika vaccine will be tested on a large experimental group before it is finally approved for the field.
So far, the Zika virus has affected 58 countries and territories and continues to expand. Initially believed to be harmless, the virus is transmitted by the mosquito species Aedes aegypti. If it is contracted by a pregnant woman, it can cause a neurological birth defect known as microcephaly.
Optimally, the Zika vaccine will be ready for public use by early 2018. Currently, more plans are being made to begin phase II trials in early 2017, which will be conducted by the U.S. National Institute of Allergy and Infectious Diseases (NSAID) based in Bethesda, Maryland.
– Jenna Salisbury
Photo: Health Impact News